This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Contineum Therapeutics, Inc. Class A (CTNM) and Exelixis (EXEL)

Tipranks - Tipranks - Thu May 7, 7:08AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on IQVIA Holdings (IQV), Contineum Therapeutics, Inc. Class A (CTNM) and Exelixis (EXEL).

Claim 55% Off TipRanks

IQVIA Holdings (IQV)

RBC Capital analyst Ryan Halsted reiterated a Buy rating on IQVIA Holdings yesterday and set a price target of $221.00. The company’s shares closed last Tuesday at $176.42, close to its 52-week low of $176.03.

According to TipRanks.com, Halsted is a 1-star analyst with an average return of -6.4% and a 36.4% success rate. Halsted covers the Healthcare sector, focusing on stocks such as Privia Health Group, Healthcare Services, and Charles River Labs. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings with a $216.75 average price target, representing a 35.6% upside. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $213.00 price target.

See today’s best-performing stocks on TipRanks >>

Contineum Therapeutics, Inc. Class A (CTNM)

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Contineum Therapeutics, Inc. Class A, with a price target of $22.00. The company’s shares closed last Tuesday at $14.39.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 10.2% and a 51.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Aardvark Therapeutics, Inc., and Neumora Therapeutics, Inc. ;'>

Currently, the analyst consensus on Contineum Therapeutics, Inc. Class A is a Strong Buy with an average price target of $20.83, implying a 46.4% upside from current levels. In a report issued on May 1, Stifel Nicolaus also maintained a Buy rating on the stock with a $29.00 price target.

Exelixis (EXEL)

In a report released today, Leonid Timashev from RBC Capital maintained a Hold rating on Exelixis, with a price target of $43.00. The company’s shares closed last Tuesday at $44.42.

According to TipRanks.com, Timashev is a 5-star analyst with an average return of 19.8% and a 57.0% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Perspective Therapeutics, and Edgewise Therapeutics. ;'>

Currently, the analyst consensus on Exelixis is a Moderate Buy with an average price target of $48.00, a 8.0% upside from current levels. In a report released today, Barclays also maintained a Hold rating on the stock with a $45.00 price target.

Read More on IQV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).